Ownership of the Laboratoires Fournier production and distribution site transfers to Recipharm

Ownership of the Laboratoires Fournier production and distribution site transfers to Recipharm

Laboratoires Fournier, a subsidiary of Solvay Pharmaceuticals and Recipharm (one of the world’s leading contract development and manufacturing organisations) are pleased to announce that they have entered into an agreement with regard to the Fontaine-Lès-Dijon (France) site. Under the agreement, Recipharm acquires the site from Laboratoires Fournier for an undisclosed sum. The site, comprising a tablet and capsule manufacturing facility and modern logistics centre, formally changed ownership on 31 December 2008, and the entire workforce have been retained by Recipharm.

This additional production capacity in France will allow Recipharm to expand further its offering into a region it has identified as having scope for growth. The company already has a sterile manufacturing plant in Monts (Indre-et-Loire), which it acquired from Astra Zeneca in July 2007. In recent years, Recipharm has benefited from significant growth and currently owns several production plants and a development centre in Europe.

Under the terms of the agreement, Recipharm receives an initial contract covering most of the current site activities. Recipharm plans to develop the site by the diversification of its customer base and product range. The acquisition offers Recipharm increased dry form production capacity complementing its capabilities in Sweden and the UK.

Commenting on this latest development, Thomas Eldered, CEO and Managing Director of Recipharm, said, “The acquisition of the Fontaine-Lès-Dijon site brings to the group major new customers, a skilled workforce and an excellent facility. It also supports our strategy to become one of the world’s leading CDMO’s. We really look forward to welcoming the employees to Recipharm“. Luc Denhaerynck, General Manager of Laboratoires Fournier, commented “we are very pleased to have found a strong industrial partner to take over the site and we are very pleased to be able to establish a successful relationship with Recipharm”.

RECIPHARM is a leading contract development and manufacturing organisation based in Europe. The Company now operates nine  manufacturing facilities in Sweden, France, UK and Switzerland and is headquartered near Stockholm, Sweden. Recipharm supplies the global biopharmaceuticals market with in excess of six hundred different products in multiple dosage forms that include solid dose granulates and powders, steriles, semi solids, beta-lactams, hormones and dry powder inhalers.    

Website: www.recipharm.com.
The company has also just announced that it has acquired a majority stake in the Astra Zeneca Biotech Laboratory (ABL) located in Sweden. The transfer took place on 1 January 2009 and develops and produces biological products on a contract basis for external companies. AstraZeneca will still retain a 20% share in this facility.

Laboratoires Fournier S.A. is a French subsidiary of SOLVAY PHARMACEUTICALS, the research driven group of companies that constitute the global pharmaceutical business of the Solvay Group.  Solvay Pharmaceuticals seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health.  Its 2007 sales were EUR 2.6 billion, and it employs more than 9,000 people worldwide. 

For more information, visit www.solvaypharmaceuticals.com.

SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels.  It employs more than 28,000 people in 50 countries.  In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity:  Chemicals, Plastics and Pharmaceuticals.  Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLB.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com.